Moleculin Biotech Inc (MBRX) Actualités

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced...

Form RW - Registration Withdrawal Request

Form 8-K - Current report

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds PR Newswire HOUSTON, Feb. 13, 2025...

Form 8-K - Current report

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R...

Form 8-K - Current report

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form 8-K - Current report